New drug combo tested for Tough-to-Treat head and neck cancer
NCT ID NCT05054439
Summary
This study is testing a new drug combination for people with advanced head and neck cancer that has come back or spread after initial treatment. It aims to see if adding the experimental drug SI-B001 to the chemotherapy drug paclitaxel is safe and can help control the cancer. The trial is for adults whose cancer got worse after previous immunotherapy and/or chemotherapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hunan Cancer Hospital
Changsha, Hunan, China
-
Shanghai Oriental Hospital
Shanghai, Shanghai Municipality, 200120, China
-
The Affiliated Cancer Hospital of Guizhou Medical University
Guiyang, Guizhou, China
-
The Second Affiliated Hospital of Guilin Medical University
Guilin, Guangxi, China
-
Union Hospital Tongji Medical College， Huazhong University of Science and Technology
Wuhan, Hubei, China
-
West China Hospital，Sichuan University
Chengdu, Sichuan, China
-
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China
Conditions
Explore the condition pages connected to this study.